Adlai Nortye Ltd.

ANL

Explore Our Financial Data > Companies > Adlai Nortye Ltd.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ANL
CIK	0001944552
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	685 U.S. HIGHWAY ONE, 2ND FLOOR, NORTH BRUNSWICK, NJ, 08902
Website	www.adlainortye.com
Phone	848-230-7430
CEO	Yang Lu
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$5.23 million
Pre-Tax Income	$-35.53 million
Net Income	$-35.53 million
Net Income to Common	$-35.53 million
EPS	N/A

View All

Balance Sheet

Cash	$8.06 million
Assets	$34.43 million
Liabilities	$42.76 million
Common Equity	$-8.32 million
Liabilities & Equity	$34.43 million

View All

Cash Flow Statement

Net Income	$-35.53 million
Cash From Operating Activities	$-33.45 million
Cash From Investing Activities	$-15.58 million
Cash From Financing Activities	$-3.81 million
Change in Cash	$-52.84 million

View All

Calculations

NOPAT	$-24.83 million
EBITDA	$-34.11 million
Price to Earnings	N/A
Price to Book	N/A
ROE	-414.01%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress

Why the AN4035 trial move matters for Adlai Nortye Group stock Adlai Nortye Group (NasdaqGM:ANL) has just dosed the first patient in its global Phase I trial for AN4035 and secured a Study May Proceed letter from the FDA, clearing expansion into the United States. The fresh AN4035 milestone comes after a strong run in Adlai Nortye Group’s stock, with a very large year-to-date share price return and a 1-year total shareholder return of about 8x. Recent 30-day and 90-day share price returns of...

Article Link

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with "Study-May-Proceed" letter SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced tha

Article Link

These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts

Ask any old-school market investor and he’ll tell you that the cliché is true, and ‘past performance cannot guarantee future returns.’ If that were true without exception, then growth investing would not be a viable option – but we all know that investors love to buy into stocks that have shown enormous growth in recent months. The ‘monster growth’ stocks are popular because investing into them is successful. The key is understanding the smart middle way, and treating stocks as individuals, with

Article Link

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed to Scientific Advisory Board SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced

Article Link

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has submitted

Article Link